Ketu Mishra-Gorur

Dr. Ketu Mishra-Gorur


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
TBTanyeri Barak
Tanyeri Barak
EREmma Ristori
Emma Ristori
AEA. Gulhan Ercan-Sencicek
A. Gulhan Ercan-Sencicek
DMDanielle F. Miyagishima
Danielle F. Miyagishima
CNCarol Nelson-Williams
Carol Nelson-Williams
MGMurat Günel
Murat Günel

1 October 2019 in Disease Models & Mechanisms
Verified
Journal Article
Open access
PDF file
KMKetu Mishra-Gorur
Ketu Mishra-Gorur
DLDaming Li
Daming Li
XMXianjue Ma
Xianjue Ma
YYYanki Yarman
Yanki Yarman
LXLei Xue
Lei Xue
TXTian Xu
Tian Xu
Targeted cell migration plays important roles in developmental biology and disease processes including metastasis. Drosophila tumors exhibit traits characteristic of human cancers, providing a powerful model to study developmental and cancer biology. We now find that cells derived from Drosophila eye disc tumors also display organ specific metastasis to invade receptive organs but not wing disc. Toll receptors are known to affect innate immunity and tumor inflammatory microenvironment by modulating the NF-κB pathway. Our RNAi screen and genetic analyses show that Toll-6 is required for migration and invasion of the tumor cells. Further, receptive organs express Toll-ligands, Spz family molecules, and ectopic Spz expression renders wing disc receptive to metastasis. Finally, Toll-6 promotes metastasis by activating JNK signaling, a key regulator of cell migration. Hence, we report Toll-6 and Spätzle as a new pair of guidance molecules mediating organ-specific metastasis behavior and highlight a novel signaling mechanism for Toll family receptors.

2 February 2017 in Genome Medicine
Verified
Journal Article
Open access
PDF file
EOE. Zeynep Erson Omay
E. Zeynep Erson Omay
OHOctavian Henegariu
Octavian Henegariu
SOSacit Bulent Omay
Sacit Bulent Omay
AHAkdes Serin Harmancı
Akdes Serin Harmancı
MYMark W. Youngblood
Mark W. Youngblood
MGMurat Günel
Murat Günel
Glioblastoma multiforme (GBM) constitutes nearly half of all malignant brain tumors and has a median survival of 15 months. The standard treatment for these lesions includes maximal resection, radiotherapy, and chemotherapy; however, individual tumors display immense variability in their response to these approaches. Genomic techniques such as whole-exome sequencing (WES) provide an opportunity to understand the molecular basis of this variability. Here, we report WES-guided treatment of a patient with a primary GBM and two subsequent recurrences, demonstrating the dynamic nature of treatment-induced molecular changes and their implications for clinical decision-making. We also analyze the Yale-Glioma cohort, composed of 110 whole exome- or whole genome-sequenced tumor-normal pairs, to assess the frequency of genomic events found in the presented case. Our longitudinal analysis revealed how the genomic profile evolved under the pressure of therapy. Specifically targeted approaches eradicated treatment-sensitive clones while enriching for resistant ones, generated due to chromothripsis, which we show to be a frequent event in GBMs based on our extended analysis of 110 gliomas in the Yale-Glioma cohort. Despite chromothripsis and the later acquired mismatch-repair deficiency, genomics-guided personalized treatment extended survival to over 5 years. Interestingly, the case displayed a favorable response to immune checkpoint inhibition after acquiring mismatch repair deficiency. Our study demonstrates the importance of longitudinal genomic profiling to adjust to the dynamic nature of treatment-induced molecular changes to improve the outcomes of precision therapies.

1 January 2025 in Nature
Verified
Journal Article
Open access
PDF file
CZCe Zhang
Ce Zhang
DLDan Liang
Dan Liang
AEA. Gulhan Ercan-Sencicek
A. Gulhan Ercan-Sencicek
ABAybike S. Bulut
Aybike S. Bulut
JCJoelly Cortes
Joelly Cortes
KBKaya Bilguvar
Kaya Bilguvar
Cerebral cortex development in humans is a highly complex and orchestrated process that is under tight genetic regulation. Rare mutations that alter gene expression or function can disrupt the structure of the cerebral cortex, resulting in a range of neurological conditions1. Lissencephaly (‘smooth brain’) spectrum disorders comprise a group of rare, genetically heterogeneous congenital brain malformations commonly associated with epilepsy and intellectual disability2. However, the molecular mechanisms underlying disease pathogenesis remain unknown. Here we establish hypoactivity of the mTOR pathway as a clinically relevant molecular mechanism in lissencephaly spectrum disorders. We characterized two types of cerebral organoid derived from individuals with genetically distinct lissencephalies with a recessive mutation in p53-induced death domain protein 1 (PIDD1) or a heterozygous chromosome 17p13.3 microdeletion leading to Miller–Dieker lissencephaly syndrome (MDLS). PIDD1-mutant organoids and MDLS organoids recapitulated the thickened cortex typical of human lissencephaly and demonstrated dysregulation of protein translation, metabolism and the mTOR pathway. A brain-selective activator of mTOR complex 1 prevented and reversed cellular and molecular defects in the lissencephaly organoids. Our findings show that a converging molecular mechanism contributes to two genetically distinct lissencephaly spectrum disorders.

12 April 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
KMKetu Mishra-Gorur
Ketu Mishra-Gorur
TBTanyeri Barak
Tanyeri Barak
LKLeon D. Kaulen
Leon D. Kaulen
OHOctavian Henegariu
Octavian Henegariu
SJSheng Chih Jin
Sheng Chih Jin
MGMurat Gunel
Murat Gunel
While somatic variants of TRAF7 (Tumor necrosis factor receptor-associated factor 7) underlie anterior skull-base meningiomas, here we report the inherited mutations of TRAF7 that cause congenital heart defects. We show that TRAF7 mutants operate in a dominant manner, inhibiting protein function via heterodimerization with wild-type protein. Further, the shared genetics of the two disparate pathologies can be traced to the common origin of forebrain meninges and cardiac outflow tract from the TRAF7- expressing neural crest. Somatic and inherited mutations disrupt TRAF7–IFT57 interactions leading to cilia degradation. TRAF7 -mutant meningioma primary cultures lack cilia, and TRAF7 knockdown causes cardiac, craniofacial, and ciliary defects in Xenopus and zebrafish, suggesting a mechanistic convergence for TRAF7 -driven meningiomas and developmental heart defects.

7 October 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
MYMark W. Youngblood
Mark W. Youngblood
ZEZeynep Erson-Omay
Zeynep Erson-Omay
CLChang Li
Chang Li
HNHINDA NAJEM
HINDA NAJEM
SCSüleyman Coșkun
Süleyman Coșkun
MGMurat Günel
Murat Günel
Hedgehog signaling mediates embryologic development of the central nervous system and other tissues and is frequently hijacked by neoplasia to facilitate uncontrolled cellular proliferation. Meningiomas, the most common primary brain tumor, exhibit Hedgehog signaling activation in 6.5% of cases, triggered by recurrent mutations in pathway mediators such as SMO. In this study, we find 35.6% of meningiomas that lack previously known drivers acquired various types of somatic structural variations affecting chromosomes 2q35 and 7q36.3. These cases exhibit ectopic expression of Hedgehog ligands, IHH and SHH, respectively, resulting in Hedgehog signaling activation. Recurrent tandem duplications involving IHH permit de novo chromatin interactions between super-enhancers within DIRC3 and a locus containing IHH. Our work expands the landscape of meningioma molecular drivers and demonstrates enhancer hijacking of Hedgehog ligands as a route to activate this pathway in neoplasia.